Researchers have shown for the first time that intermittent fasting increases the efficacy of anti-androgen therapy in prostate cancer, according to a paper reporting preclinical results published Aug ...
The U.S. Food and Drug Administration (FDA) has granted fast track designation to Alessa Therapeutics for its lead product ...
SAN CARLOS, Calif.--(BUSINESS WIRE)--Alessa Therapeutics (“Alessa”), a clinical-stage biopharmaceutical company advancing novel localized drug delivery technology for the treatment of early-stage ...
City of Hope®, one of the largest and most advanced cancer research and treatment organizations in the United States with its National Medical Center ranked among the nation’s top cancer centers by U.
In preclinical prostate cancer models, HLD-0915 treatment resulted in tumor shrinkage and declines in prostate-specific antigen. The Food and Drug Administration (FDA) has granted Fast Track ...
Decades ago, doctors created a test to determine which breast cancer patients should receive hormone therapy. Now, ...
BUFFALO, N.Y. – Researchers have shown for the first time that intermittent fasting increases the efficacy of anti-androgen therapy in prostate cancer, according to a paper reporting preclinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results